Loading...
NPI 1548655053 · Jackson, MS · Ambulatory Surgical Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mississippi Urology Outpatient Surgery Center, LLC is a ambulatory surgical clinic/center provider located in Jackson, Mississippi. This profile covers 26 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Mississippi Urology Outpatient Surgery Center, LLC |
| Address | 501 Marshall St |
| City | Jackson |
| State | MS |
| ZIP | 39202 |
| Taxonomy | Ambulatory Surgical Clinic/Center |
| NPI Enumerated | April 1, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.8M |
| Medicaid | $9.8K |
MISSISSIPPI UROLOGY OUTPATIENT SURGERY CENTER, LLC is an ambulatory surgical clinic/center in JACKSON, MS with an NPI enumerated 2015-04-01 (~11 years ago). Its CPT/HCPCS mix is concentrated in endoscopic urology and implantable-device procedures, suggesting an ASC focused on diagnostic and therapeutic cystoscopy, stone management, transurethral prostate procedures, and sacral/peripheral neurostimulator implantation.
Medicare revenue is $1.8M and is materially concentrated: the precomputed top three Medicare codes (C9740, 64590, 52000) account for 46.3% of the provider’s Medicare revenue. Those three codes individually are C9740 $345.6K (19.2%), 64590 $279.3K (15.5%), and 52000 $210.2K (11.7%), indicating both higher-priced implant procedures and high-volume cystoscopy contribute meaningfully to Medicare receipts.
On Medicaid the provider reports $9.8K total revenue and the top three Medicaid codes account for 100.0% of Medicaid revenue; Medicaid billing is effectively concentrated in one code, 52000 (166 claims, $59 avg paid/claim, $9.8K revenue), with other listed G-codes producing claims but $0 in paid Medicaid revenue. This pattern makes the facility functionally Medicare-dominant at scale while still providing the same diagnostic cystoscopy service to Medicaid enrollees.
Competitive standing on key Medicare service lines is mixed but includes notable national outlier positions: the provider is an "extreme outlier" on 52000 (1.1K claims, ranks #19 of 8548 nationally, 100th percentile) and on several surgical procedure codes such as 52648 (63 claims, $99K, rank #6 of 451, 99th percentile) and 55700 (230 claims, $139.2K, rank #33 of 4425, 99th percentile). By contrast, its neurostimulator implantation codes (e.g., 64590: 20 claims, rank #183 of 561, 65th percentile; 64561: 44 claims, rank #131 of 564, 76th percentile) are at or above typical national volumes but are not extreme outliers.
Operationally, the code-level volumes show a dual profile: very high-volume diagnostic/endoscopic throughput (52000 at 1.1K Medicare claims and 166 Medicaid claims) alongside lower-frequency, high-dollar implant procedures (for example 64590 is 20 claims with $13967 avg paid/claim yielding $279.3K). This mix implies the center runs steady endoscopy case flow while also performing episodic device implantations that drive a substantial share of revenue per case.
There are notable utilization and revenue-shape nuances worth attention for contracting or network analysis: J0585 appears as very high claim-count activity (10.7K claims) but low payment per unit ($5 avg) and limited revenue contribution ($53.3K), whereas a small number of high-paid implant claims (e.g., 64590, C9740) produce outsized revenue. These patterns indicate the provider’s financial performance is sensitive to volume in a handful of high-reimbursement implant codes in addition to its bulk cystoscopy throughput.
For payer strategy and oversight, the provider is effectively single-payer dominant: Medicare ($1.8M) dwarfs Medicaid ($9.8K) in scale, so Medicare utilization and specialty mix will primarily determine the facility’s financial and competitive profile. Given the concentration (46.3% of Medicare revenue from the top three codes) and several national extreme-outlier rankings on core urology procedures, this provider presents as a specialized, high-volume ambulatory urology center that may be prioritized for referral networks or device-service contracts rather than broad primary-care billing relationships.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
26 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| C9740 | Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants | 70 | $5,160 | $345.6K |
| 64590 | The provider inserts or replaces a peripheral, sacral, or gastric neurostimulator pulse generator or receiver. The system is one that requires surgical creation of a pocket for placement and that… | 20 | $13,970 | $279.3K |
| 52000 | In this procedure, the provider performs an examination of the interior of the bladder, the urethra, and the ureteric openings by means of a cystourethroscope, a thin flexible or rigid tube with a… | 1,070 | $200 | $210.2K |
| 64561 | The provider, under imaging guidance, implants electrodes around nerves in the sacral region to reduce the pain along the path of the nerve. | 40 | $3,450 | $151.8K |
| 55700 | Code deleted December 31, 2025. | 230 | $610 | $139.2K |
| 52648 | Transurethral resection of the prostate is performed in cases of BPH (benign prostate hyperplasia) which commonly occurs in middle–aged and elderly men, often causing lower urinary symptoms, with… | 60 | $1,570 | $99K |
| 64581 | The provider uses an open approach to implant a sacral nerve neurostimulator electrode array. Placement is transforaminal, meaning through the foramen (the opening sacral nerves run through). This… | 20 | $3,840 | $88.4K |
| 52287 | The provider performs an examination of the interior of the bladder, the urethra, and the ureteric openings by means of a cystoscope. He then inserts a needle and injects a neurolytic drug into the… | 90 | $610 | $56K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 10,650 | $10 | $53.3K |
| 52353 | The provider performs a cystourethroscopy, the inspection of the interior of the bladder, the urethra, prostatic urethra, and ureteric openings using a cystoscope passed through the urethra and into… | 30 | $1,630 | $50.4K |
Showing 1–10 of 26
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 26 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
26 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| C9740 | 3 | 10 | 70 | $5,000 | $349.8K |
| 64590 | 14 | 20 | 30 | $6,100 | $201.4K |
| 64561 | 10 | 20 | 40 | $2,180 | $141.6K |
| J0585 | 9 | 30 | 5,890 | $1 | $46.9K |
| 64581 | 2 | 10 | 20 | $1,860 | $39K |
| 52648 | 1 | 10 | 20 | $1,030 | $26.7K |
| 51715 | 3 | 10 | 30 | $900 | $22.5K |
| 52356 | 17 | 30 | 20 | $600 | $19.2K |
| 52000 | 1 | 70 | 90 | $130 | $18.3K |
| 52281 | 12 | 20 | 30 | $320 | $17.1K |
Showing 1–10 of 26
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 52000 | In this procedure, the provider performs an examination of the interior of the bladder, the urethra, and the ureteric openings by means of a cystourethroscope, a thin flexible or rigid tube with a… | 170 | $60 | $9.8K |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 1,350 | $0 | $0 |
| G8915 | Patient documented not to have experienced a hospital transfer or hospital admission upon discharge from asc | 730 | $0 | $0 |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | 50 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 52000 | In this procedure, the provider performs an examination of the interior of the bladder, the urethra, and the ureteric openings by means of a cystourethroscope, a thin flexible or rigid tube with a… | 3 | 10 | 70 | $90 | $16.4K |
| G8918 | Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis | 25 | 40 | 140 | $1 | $590 |
| G8907 | Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer… | 13 | 60 | 520 | $1 | $200 |
| G8915 | Patient documented not to have experienced a hospital transfer or hospital admission upon discharge from asc | 1 | 10 | 730 | $0 | $0 |
Other providers in the same ZIP code as Mississippi Urology Outpatient Surgery Center, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.